Meet Our Team
Board of Directors
Leslie Henshaw is a Partner on the Private Transactions team at Deerfield Management where she works with a variety of healthcare services and healthcare information technology companies that are both current and potential investment partners. Before joining Deerfield in 2005, Leslie was co-manager of an ING branded healthcare hedge fund she launched in 2000. Prior to that she spent 11 years in the investment banking, high yield research and equity research departments at Furman Selz and ING, where she focused exclusively on companies in the healthcare arena. She also spent two years as a member of the national healthcare consulting practice of Price Waterhouse. Leslie graduated with High Honors from Wesleyan University and earned her M.B.A. from the University of Chicago. She also holds Board seats at Veterinary Practice Partners, Epion Health, and Recovery Centers of America.
Jeff Kindler is a Venture Partner at Lux Capital and a senior advisor to Paragon Pharmaceuticals. Mr. Kindler was formerly the Chairman and CEO of Pfizer, the world's largest research-based biopharmaceutical company. He also serves on the boards of AgaMatrix; Intrexon; Sheridan Healthcare, a provider of healthcare solutions to physicians, hospitals, and outpatient centers; PPD, a global contract drug discovery and development research organization; Tufts University; and the National Center on Addiction and Substance Abuse at Columbia University.
Richard Foster is the Managing Partner of the Millbrook Management Group, LLC and a Venture Partner at Lux Capital. Prior to forming Millbrook, Mr. Foster was with McKinsey & Company for 30 years. While at McKinsey, he served as a Senior Partner and Director for 22 years before retiring from the firm in 2004. Mr. Foster co-founded the firm’s high technology, chemicals, healthcare, and private equity practices. Mr. Foster is also a member of the board of directors of several companies including Athenahealth, Memorial Sloan Kettering Cancer Center, and Yale School of Medicine Dean’s Advisory Board.
Paul Daoust is currently Non-Executive Chairman of the Board of HighRoads, an industry leader in plan management and benefits compliance. Mr. Daoust is a recognized leader in both the human resources consulting and technology industries, and served as HighRoads’s CEO for 4 years. Prior to HighRoads, he served as chairman and CEO of GRX Technologies Inc. Paul currently sits on the board of directors for publicly traded Caldwell Partners (TSX:CWL) and for Provant Health Solutions, a privately held wellness company. He is also a member of the advisory boards for XBInsight, Bullseye Engagement, and Brodeur Partners.
Sean Glass is Founder & CEO of Advantia Health. Before Advantia, Sean founded and continues to manage Acceleprise.VC, a leading early stage enterprise software venture capital fund. Previously, Sean founded the higher education focused online financial services firm, Higher One. At Higher One he served as founding president and then as part of the executive team as Chief Marketing Officer for 8 years. During that time, Higher One reached profitability and in 2008 was in the top 100 of the Inc 500 list and ranked #12 on the Entrepreneur Hot 100 list of fastest growing U.S. private companies. Higher One went public in 2010 (NYSE:ONE).
Dr. Peter Glass is Founder & Chief Medical Officer of Advantia Health. Prior to joining Advantia Health, Dr. Glass was Professor and Chairman of Anesthesia at the State University of New York at Stony Brook. Throughout his career, he has been intimately involved in the growth of ambulatory surgery, both through his research concerning the development of propofol, remifentanil desflurane, and pain management, and through his roles on the Board of the Society for Ambulatory Anesthesia (SAMBA), where he was also President in 2010.
Frederick Frank is a founder of EVOLUTION Life Science Partners and a former vice chairman of Lehman Brothers, Barclays Capital, and Peter J. Solomon Company. Throughout his career Mr. Frank has provided investment banking services to an extensive number of life sciences companies and has been involved in hundreds of financings, strategic alliances, and merger and acquisition transactions in the global healthcare industry. Most recently, he advised CV Therapeutics in its IPO and then sale to Gilead Sciences, and OSI Pharmaceuticals in its sale to Astellas Pharma.
Paul Brown is currently an adjunct professor at the University of Utah's Eccles School of Business. Previously, Mr. Brown was a managing director at Sandbox Industries in Chicago, where he co-founded the firm's healthcare venture funds and founded an innovation consulting practice; president for 10 years at the BlueCross BlueShield Association; and a partner in the Chicago office of Kirkland & Ellis LLP. He has also advised and served on the boards of many companies in the healthcare industry including Capson, Phreesia, Patientco, and Bloom Health.